Abstract
We tested two metabotropic glutamate receptor 2/3 (mGluR2/3) agonist prodrugs – pomaglumetad (POMA) and TS-134 – including a high-dose of POMA that was four times the dose tested in the failed phase schizophrenia III trials – in two proof of mechanism, Phase Ib studies using identical pharmacoBOLD target-engagement methodology.
The POMA study was a double-blind, NIMH-sponsored, 10-day study of 80 or 320 mg/d POMA or placebo (1:1:1 ratio), designed to detect d>0.8 sd between-group effect-size differences. The TS-134 study was a single-blind, industry-sponsored, 6-day study of 20 or 60 mg/d TS-134 or placebo (5:5:2 ratio), designed to permit effect-size estimation for future studies. Primary outcomes were ketamine-induced changes in pharmacoBOLD in the dorsal anterior cingulate cortex (dACC) and Brief Psychiatric Rating Scale (BPRS).
95 healthy controls were randomized to POMA and 63 to TS-134. High-dose POMA had significant within and between-group reduction in ketamine-induced BPRS total symptoms (p<0.01, d=-0.41; p=0.04, d=-0.44, respectively) but neither POMA dose significantly suppressed ketamine-induced dACC pharmacoBOLD. In contrast, low-dose TS-134 had significant/trend level, moderate to large within and between group effects on BPRS positive symptoms (p=0.02, d=-0.36; p=0.008, d=-0.82, respectively) and dACC pharmacoBOLD (p=0.004, d=-0.56; p=0.079, d=-0.50, respectively) using pooled across-study placebo data.
High-dose POMA exerted significant effects on clinical symptoms, but not on target engagement, suggesting a higher dose may yet be needed. TS-134 20 mg showed evidence of symptom reduction and target engagement, indicating a curvilinear dose-response curve. These results warrant further investigation of mGluR2/3 and other glutamate-targeted treatments for schizophrenia.
Competing Interest Statement
Dr. Kantrowitz reports having received consulting payments within the last 24 months from Krog & Partners Incorporated, IQVIA, Alphasights, Charles River Associates, Putnam Associates, Third Bridge, Piper Jaffray, MEDACorp, Simon Kucher, LifeSci Capital, ECRI Institute, System Analytic and BVF Partners. He has served on the Aristada Schizophrenia Advisory Board for Alkermes and the MedinCell Psychiatry Advisory Board. He has conducted clinical research supported by the NIMH, Sunovion, the Stanley Foundation, Takeda, Taisho, Lundbeck, Boehringer Ingelheim, NeuroRX, Teva and Lilly within the last 24 months. Dr. Kantrowitz a co-investigator on a study that receives lumeteperone and reimbursement for safety testing for an investigator-initiated research from Intra-Cellular Therapies Inc. He owns a small number of shares of common stock from GSK. Dr. Goff does not accept any personal financial remuneration for consulting, speaking or research activities from any pharmaceutical, biotechnology, or medical device companies. He has received funding for research from Avanir Pharmaceuticals which does not contribute to his compensation. He has served as a consultant or advisory board member for the Welcome Trust, Intra-Cellular Therapies, Takeda, and Avanir Pharmaceuticals for which he receives no personal remuneration. Dr. Marder has served on advisory boards for Sunovion, Roche, Boeringer Ingellheim, and Merck. He has received research support from Takeda and Boeringer Ingelheim. Dr. Girgis reports research support from BioAdvantex, Genentech, Otsuka and Allergan and receives royalties from Routledge/Taylor and Francis. Dr. Green has been a consultant for Biogen, Click Therapeutics, Lundbeck, and Roche, and he is on the Scientific Board of Cadent. Dr. Krystal reports having received consulting payments from AstraZeneca Pharmaceuticals, Biogen, Biomedisyn Corporation, Bionomics, Boehringer Ingelheim International, COMPASS Pathways, Concert Pharmaceuticals, Epiodyne, EpiVario, Heptares Therapeutics, Janssen Research & Development, Otsuka America Pharmaceutical, Perception Neuroscience Holdings, Spring Care, Sunovion Pharmaceuticals, Takeda Industries, and Taisho Pharmaceutical. He has served on advisory boards for Bioasis Technologies, Biohaven Pharmaceuticals, BioXcel Therapeutics, BlackThorn Therapeutics, Cadent Therapeutics, Cerevel Therapeutics, EpiVario, Eisai, Lohocla Research Corporation, Novartis Pharmaceuticals Corporation and PsychoGenics. He is a co-sponsor of a patent for the intranasal administration of ketamine for the treatment of depression and for the treatment of suicide risk that was licensed by Janssen Pharmaceuticals; has a patent related to the use of riluzole to treat anxiety disorders that was licensed by Biohaven Pharmaceuticals; has stock or stock options in Biohaven Pharmaceuticals, Blackthorn Therapeutics, Luc Therapeutics, Cadent Pharmaceuticals, Terran Biosciences, Spring Healthcare, and Sage Pharmaceuticals. He serves on the Board of Directors of Inheris Pharmaceuticals. He receives compensation for serving as editor of the journal Biological Psychiatry. Dr. Javitt reports having received consulting payments from Pfizer, FORUM, Autifony, Glytech, Lundbeck, Concert, and Cadence. He holds intellectual property rights for use of NMDA modulators in treatment of neuropsychiatric disorders. He holds equity in Glytech, AASI, and NeuroRx, and serves on the advisory board of Promentis, Phytec and NeuroRx. Dr. Lieberman does not accept any personal financial remuneration for consulting, speaking or research activities from any pharmaceutical, biotechnology, or medical device companies. He receives funding and medication supplies for investigator-initiated research from Denovo, Taisho, Pfizer, Sunovion, and Genentech, and for company sponsored phase II, III, and IV studies from Alkermes, Allergan, Boehringer Ingelheim and Sunovion which does not contribute to his compensation. He receives medication supplies for investigator-initiated research from Intra-Cellular Therapies Inc. He is a consultant or advisory board member of Intra-Cellular Therapies, Takeda, Pierre Fabre, Karuna, Pear Therapeutics, Systems-1, and Psychogenics for which he receives no remuneration. He is a paid consultant for Bracket, a clinical research services organization, and holds a patent from Repligen that yields no royalties. Dr. Grinband, Dr. Kegeles, Dr. Yang, Dr. Lee, Dr. Sobeih, Dr. Lahti, Dr. Horga, Dr. Potter, Dr. Wall and Mr. Choo reports no financial relationships with commercial interests.
Clinical Trial
Clinicaltrials.gov: NCT02919774, NCT03141658
Funding Statement
The POMA study was supported by the FAST-PS contract (HHSN271201200007I) from NIMH. The TS-134 study was supported by Taisho Pharmaceutical R&D Inc.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data for FAST study is available at https://nda.nih.gov
